JP2020530478A - 免疫応答を強化する方法 - Google Patents

免疫応答を強化する方法 Download PDF

Info

Publication number
JP2020530478A
JP2020530478A JP2020508049A JP2020508049A JP2020530478A JP 2020530478 A JP2020530478 A JP 2020530478A JP 2020508049 A JP2020508049 A JP 2020508049A JP 2020508049 A JP2020508049 A JP 2020508049A JP 2020530478 A JP2020530478 A JP 2020530478A
Authority
JP
Japan
Prior art keywords
seq
uspa2
immunogenic composition
pila
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020508049A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530478A5 (enExample
Inventor
クマール アローラ，アシュワニ
クマール アローラ，アシュワニ
ヴェイナンツ，ヴィンセント
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム, グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2020530478A publication Critical patent/JP2020530478A/ja
Publication of JP2020530478A5 publication Critical patent/JP2020530478A5/ja
Priority to JP2023080924A priority Critical patent/JP2023103380A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020508049A 2017-08-14 2018-08-13 免疫応答を強化する方法 Pending JP2020530478A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023080924A JP2023103380A (ja) 2017-08-14 2023-05-16 免疫応答を強化する方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762545010P 2017-08-14 2017-08-14
US62/545,010 2017-08-14
US201862633263P 2018-02-21 2018-02-21
US62/633,263 2018-02-21
PCT/EP2018/071860 WO2019034575A1 (en) 2017-08-14 2018-08-13 Methods of boosting immune responses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023080924A Division JP2023103380A (ja) 2017-08-14 2023-05-16 免疫応答を強化する方法

Publications (2)

Publication Number Publication Date
JP2020530478A true JP2020530478A (ja) 2020-10-22
JP2020530478A5 JP2020530478A5 (enExample) 2021-08-26

Family

ID=63350516

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020508049A Pending JP2020530478A (ja) 2017-08-14 2018-08-13 免疫応答を強化する方法
JP2023080924A Pending JP2023103380A (ja) 2017-08-14 2023-05-16 免疫応答を強化する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023080924A Pending JP2023103380A (ja) 2017-08-14 2023-05-16 免疫応答を強化する方法

Country Status (8)

Country Link
US (1) US11723966B2 (enExample)
EP (1) EP3641808A1 (enExample)
JP (2) JP2020530478A (enExample)
CN (1) CN110996994A (enExample)
BR (1) BR112020001768A2 (enExample)
CA (1) CA3072018A1 (enExample)
MX (1) MX2020001820A (enExample)
WO (1) WO2019034575A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022543264A (ja) * 2019-08-05 2022-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロテインｄポリペプチドを含む組成物を調製するプロセス
EP4294433A1 (en) * 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Immunogenic composition, use and methods
WO2023194971A2 (en) * 2022-04-08 2023-10-12 St. Jude Children's Research Hospital Immunogenic compositions and methods for reducing transmission of pathogens

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017507181A (ja) * 2014-02-24 2017-03-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｕｓｐａ２タンパク質構築物およびそれらの使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
SE466259B (sv) * 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69740108D1 (de) * 1996-12-20 2011-03-10 Univ Texas Moraxella catarrhalis antigene uspa1 und uspa2
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
EP2292632A3 (en) 2000-09-26 2012-07-25 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
WO2007018463A2 (en) * 2005-08-10 2007-02-15 Arne Forsgren Ab Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
MX2008009280A (es) 2006-01-17 2008-12-12 Arne Forsgren Una nueva proteina de haemophilus influenzae expuesta en la superficie (proteina e; pe).
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017507181A (ja) * 2014-02-24 2017-03-16 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｕｓｐａ２タンパク質構築物およびそれらの使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
バイオ医薬品と再生医療, JPN6022028706, 2016, pages 86 - 87, ISSN: 0005082087 *
免疫学イラストレイテッド, JPN6022028705, 1990, pages 99 - 103, ISSN: 0005082086 *
砂川慶介 他: "無莢膜型インフルエンザ菌（ＮＴＨｉ）の疫学", 感染症学雑誌, vol. 第８５巻、第３号, JPN6022028707, 2011, pages 227 - 237, ISSN: 0005082088 *

Also Published As

Publication number Publication date
CA3072018A1 (en) 2019-02-21
CN110996994A (zh) 2020-04-10
EP3641808A1 (en) 2020-04-29
US11723966B2 (en) 2023-08-15
WO2019034575A1 (en) 2019-02-21
MX2020001820A (es) 2020-03-20
US20200197504A1 (en) 2020-06-25
BR112020001768A2 (pt) 2020-09-29
JP2023103380A (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
JP2022078317A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓに対して免疫化するための組成物
JP2023103380A (ja) 免疫応答を強化する方法
JP6494527B2 (ja) 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原
JP5931724B2 (ja) ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｎｅｕｍｏｎｉａｅに対するワクチンおよび組成物
JP6126993B2 (ja) 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ）に対するワクチン及び組成物
TWI234463B (en) Vaccine composition for treating streptococcus pneumoniae and respiratory syncytial virus infection, and preparation method thereof
TW201223542A (en) Non-lipidated variants of Neisseria meningitidis ORF2086 antigens
KR101905278B1 (ko) 나이세리아 메닌지티디스 조성물 및 그의 방법
JP2010172332A (ja) Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅ誘発性疾患のためのキメラワクチン
JP2017507181A (ja) Ｕｓｐａ２タンパク質構築物およびそれらの使用
JP6379041B2 (ja) ストレプトコッカス・ニューモニエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ）に対する融合抗原ワクチンおよび組成物
CN110662557A (zh) 免疫原性组合物、用途和治疗方法
AU2011336366B2 (en) Composition for immunization against Streptococcus pneumoniae
JP2009500037A5 (enExample)
JP2015129165A (ja) 分類不能（ｎｏｎ−ｔｙｐｅａｂｌｅ）インフルエンザ菌（Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅ）ワクチンおよびその使用
JP2025148354A (ja) プロテインｄポリペプチドを含む組成物を調製するプロセス
JP6401148B2 (ja) 抗原および抗原の組み合わせ
US20230233667A1 (en) Coronavirus vaccine
AU2008226340B2 (en) Treatment or prophylaxis of asthma
US20240148849A1 (en) Immunogenic composition, use and methods
WO2026068728A1 (en) A klebsiella pneumoniae vaccine
JP2025514671A (ja) ＳＡＲＳ－ＣｏＶ－２ワクチン組成物
HK40105641A (en) Vaccines against coronavirus and methods of use
JP2013510188A (ja) 黄色ブドウ球菌に由来する菌血症関連抗原
HK1172254A (en) Vaccines and compositions against streptococcus pneumoniae

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230516

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230523

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230616